ANGLE plc (GB:AGL) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ANGLE plc has unveiled promising research indicating that its Parsortix system can effectively capture circulating tumor cells (CTCs) in prostate cancer patients, potentially aiding the development of targeted therapies. This breakthrough could enhance patient stratification in clinical trials, improving outcomes by tailoring treatments to specific biomarkers. With 67% of localized and 77% of treated patients showing positive biomarkers, ANGLE’s technology could revolutionize cancer treatment strategies.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
